DGAP-News: STRATEC reports on first three months of 2013
(firmenpresse) - DGAP-News: STRATEC Biomedical AG / Key word(s): Quarter
Results/Interim Report
STRATEC reports on first three months of 2013
07.05.2013 / 07:27
---------------------------------------------------------------------
STRATEC reports on first three months of 2013
- Sales increase by 14.1% to EUR 29.2 million in Q1/2013
(Q1/2012: EUR 25.6 million*)
- EBIT margin of 15.1% in Q1/2013, up from 12.2% in Q4/2012
(Q1/2012: 17.0%*)
- Consolidated net income of EUR 3.5 million in Q1/2013
(+3.1%; Q1/2012: EUR 3.4 million)
- Earnings per share of EUR 0.30 in Q1/2013
(+3.4%; Q1/2012: EUR 0.29)
- Updated company forecast planned for release by end of H1/2013
Birkenfeld, May 7, 2013
STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) today
announced its results for the period from January 1, 2013 to March 31, 2013
upon the publication of its Interim Report as of March 31, 2013.
Key figures (EUR 000s) 01.01.- 03.31.2013 01.01.- 03.31.2012 Change* 2012 figure adjusted for a one-off item of EUR 3.3 million due to an
Sales 29,173 25,573* +14.1%
EBIT 4,406 4,349 +1.3%
EBIT margin (%) 15.1 17,0* ---
Consolidated net income 3,544 3,439 +3.1%
Earnings per share (EUR) 0.30 0.29 +3.4%
income-neutral reclassification from unfinished services and prepayments
received upon the write-down of a development project. On an unadjusted
basis, sales for the first quarter of 2012 amounted to EUR 28.8 million and
the corresponding EBIT margin amounted to 15.1%.
Financial performance
Sales performed positively in the first quarter of 2013 and increased
year-on-year by 14.1%. This growth was driven both by sound developments in
the volume of analyzer systems delivered, and by a recovery in the service
parts business. The share of sales generated with servicing parts continued
to recover compared with 2012 as a whole, and rose significantly compared
with the weak final quarter of 2012. Due not least to this factor, the EBIT
margin of 15.1% for the first three months of 2013 was improved compared to
the overall 2012 financial year (14.4%), and most visibly improved when
compared to the final quarter of last year (12.2%). Based on current
developments, STRATEC expects the positive trend observed so far in 2013 to
date to continue. At EUR 3.5 million, consolidated net income was up 3.1%
up on the previous year's figure, while earnings per share rose by 3.4% in
the first three months. The tax rate amounted to 17.8% in the first
quarter.
On an unadjusted basis, sales and the EBIT margin for the first quarter of
the previous year (2012) amounted to EUR 28.8 million and 15.1%
respectively.
Initial progress has been made in enhancing the profitability of systems
newly launched onto the market, as stated in the 2012 financial year, and
losses from the individual subsidiaries have reduced further following
completion of the investment programs implemented in 2012.
The company plans to update its forecast for 2013 and subsequent years in
the course of the first half of 2013.
Project development
Additional market launches and approvals of analyzer systems are expected
in the current and coming years. Further development milestones have been
reached to this end. Moreover, measures continue to be implemented to
extend capacities within the company's existing structures.
One of the development and production projects started in 2012 was
contractually finalized and signed in the first quarter of 2013. Further
projects have reached promising stages of negotiation.
Other developments
The volumes of in-vitro-diagnostics tests reported by leading global
laboratory operators give reason to expect only a slow recovery in the
market. The associated share of sales STRATEC generates with service parts
is currently developing stably and has recovered slightly compared with
2012. Our customers' forecasts for analyzer systems continue not to be
affected by government austerity or fiscal policy measures in the Euro or
Dollar regions.
The company's Annual General Meeting will be held in Pforzheim on June 6,
2013. The Board of Management and the Supervisory Board are proposing a
dividend of EUR 0.50 per share for approval by the Annual General Meeting.
Development in staff totals
Including temporary employees, the STRATEC Group had a total of 541
employees as of March 31, 2013 (March 31, 2012: 512). The company's
workforce thus grew by a further 14 employees compared with December 31,
2012.
Outlook
Our ability to issue precise forecasts continues to be limited by several
external factors, such as capacity utilization rates at installed systems,
the timing of further market launches, the planned production ramp-ups for
new systems, further consolidation in the IVD market, and macroeconomic
market factors. Based on the indicators and forecasts available to us, and
given our current business performance, we expect to generate sales growth
accompanied by increasing profitability in 2013. We plan to issue an update
of the company forecast for the current financial year and subsequent years
in the course of the first half of 2013.
Further details can be found in our Interim Report as of March 31, 2013
published at www.stratec.com>Investor Relations>IR News>Financial
Reports.
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, as system solutions to
laboratories, blood banks and research institutes around the world. The
company develops its products on the basis of its own patented
technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
AndréLoy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir(at)stratec.com
www.stratec.com
End of Corporate News
---------------------------------------------------------------------
07.05.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info(at)stratec.com
Internet: www.stratec.com
ISIN: DE0007289001WKN: 728900
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
209894 07.05.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.05.2013 - 07:27 Uhr
Sprache: Deutsch
News-ID 256688
Anzahl Zeichen: 8294
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 252 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: STRATEC reports on first three months of 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
STRATEC Biomedical AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
